Cytori Provides Twelve Month Data Update on Scleradec-I Trial
13 April 2015 - 2:00PM
Business Wire
Cytori Therapeutics, Inc. (NASDAQ: CYTX) announced today
preliminary 12 month follow-up data from the 12 patient
investigator initiated Scleradec-I clinical trial conducted by
Prof. B. Granel and Prof. G. Magalon from the Assistance Publique
des Hôpitaux de Marseille.
In the previously published six month follow-up data, Cytori’s
ECCS-50 therapeutic showed:
- Improvement in Cochin Hand Function
Scale (CHFS) from mean of 48.5 at baseline to 21.2 at six
months
- Improvement in Hand Pain (Visual Analog
Scale) from mean of 59.4 at baseline to 17.8 at six months
- Improvement in Raynaud’s Condition
Score (RCS) from mean of 7.2 at baseline to 2.9 at six months
- Improvement in Scleroderma Health
Assessment Questionnaire (SHAQ) score from mean of 1.4 at baseline
to 0.8 at six months
The manuscript describing these data in detail can be viewed at
http://ard.bmj.com/content/early/2014/08/10/annrheumdis-2014-205681.long.
A preliminary assessment for 12 month follow-up data has been
reviewed by the Company which management believes reflects:
- No reports of adverse events or safety
concerns
- Average values for CHFS, RCS, and SHAQ
score are statistically consistent with those at the 6 month follow
up visit
- While the average hand pain at 12
months was lower than that at baseline (reflecting overall symptom
improvement over baseline), there was an approximately 50%
reduction in the average therapeutic benefit on hand pain from six
to twelve months
The investigators have prepared and submitted for publication a
scientific manuscript based on final 12 month data. Once this
manuscript has been accepted for publication and a publication date
announced, Cytori will provide an update to investors.
About Cytori Therapeutics, Inc.
Cytori Therapeutics is a late stage cell therapy company
developing autologous cell therapies from adipose tissue to treat a
variety of medical conditions. Data from preclinical studies and
clinical trials suggest that Cytori Cell Therapy™ acts principally
by improving blood flow, modulating the immune system, and
facilitating wound repair. As a result, Cytori Cell Therapy™ may
provide benefits across multiple disease states and can be made
available to the physician and patient at the point-of-care through
Cytori’s proprietary technologies and products. For more
information: visit www.cytori.com.
Cytori Therapeutics, Inc.Shawn Richardson,
1-858-875-5279ir@cytori.com
Cytori Therapeutics (NASDAQ:CYTX)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Cytori Therapeutics (NASDAQ:CYTX)
Historical Stock Chart
Von Mai 2023 bis Mai 2024
Echtzeit-Nachrichten über Cytori Therapeutics Inc (NASDAQ): 0 Nachrichtenartikel
Weitere Cytori Therapeutics (MM) News-Artikel